More than 20 lakh patients of ischaemic heart disease-led myocardial infarction can benefit from a life-saving clot-buster drug in India. At the turn of the century, its availability in India was poor and no domestic production existed until the first Council of Scientific and Industrial Research licensee began production in 2001-02. Its price was less than half that of the drug made by a multinational company, the major supplier in the market at that time. Its supply increased to 1,20,000 doses in 2011 after other producers entered the market. Prices dropped by more than 50%. The economic impact of streptokinase technologies, or the value that would be lost if the licensee's streptokinase did not exist, is about `580 crore for the patients.
